Please assess the completion status of the following clinical trial:

Trial Title: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key inclusion criteria include:~* Age greater than or equal to 18 years upon entry into initial screening.~* Documented history of migraine with or without aura according to the International Headache Society (IHS) International Classification of Headache Disorders, Third Edition (ICHD-III) for greater than or equal to 12 months.~* Have high-frequency episodic migraine (HFEM): Defined as history of ≥ 7 to \< 15 migraine days and \< 15 headache days per month on average during the 3 months prior to screening.~* History of ≥ 4 migraine attacks of at least moderate severity per month on average during the 3 months prior to screening.~* History of treatment failure with at least 1 preventive treatment for migraine. Failure of preventive treatment for migraine is defined as treatment discontinuation due to lack of efficacy, adverse event, or general poor tolerability.~* Regular use of an oral triptan (using only eletriptan, rizatriptan, sumatriptan, or zolmitriptan) for acute migraine treatment, and typically initiating acute treatment with an oral triptan on \> 50% of attacks of at least moderate pain intensity. Regular use is defined as ≥ 4 days of oral triptan use per month during the 3 months prior to screening.~Key exclusion criteria include:~* History of hemiplegic migraine, cluster headache, or other trigeminal autonomic cephalalgia.~* Has any medical contraindication to the use of an oral triptan.~* Previously treated with erenumab.~* Previously treated with a gepant (small molecule calcitonin gene related peptide receptor \[CGRP-R\] antagonist) in a preventive fashion in a manner consistent with migraine prevention that either:~  1. In the opinion of the investigator, did not offer any evidence of a therapeutic response or~ 2. Was discontinued for less than 12 weeks from the date of initial screening or~ 3. Was previously discontinued due to a known adverse drug reaction~* Currently being treated with lasmiditan and/or a gepant in the acute setting.~* No therapeutic response with greater than 4 of the defined medication categories after an adequate therapeutic trial.~* Currently has a history of consistent excellent response to oral triptans, defined as achievement of pain-freedom in ≤ 1 hour for ≥ 50% of treated attacks of at least moderate pain intensity during the 3 months prior to screening.~* Use of triptans administered via a non-oral (e.g. subcutaneous \[SC\] or intranasal delivery systems) or sublingual route at the time of screening, during the run-in and baseline periods, and throughout the study duration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): The 4-month DBTP has 2 phases:~* Main double-blind treatment phase (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~* Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden.
- Placebo (Type: EXPERIMENTAL): The 4-month DBTP has 2 phases:~* Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~* Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptan therapy as well as non-ictal burden.

Based on this trial design, predict the completion outcome and termination type (if applicable).